Short answer
VERACYTE, INC. (VCYT) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $152M (up 15.1% year over year) with net income of $32M.
Q3 2026 key financials · XBRL
- Revenue
- $152M
- +15.1% YoY · +1.0% QoQ
- Net income
- $32M
- +64.6% YoY · +23.6% QoQ
- Operating margin
- 10.9%
- Gross margin
- 70.6%
- EPS (diluted)
- $0.38
- +58.3% YoY · +22.6% QoQ
Source: XBRL data from the VERACYTE, INC. (VCYT) Q3 2026 10-Q on SEC EDGAR. USD.
VERACYTE, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $151.8M, up 15% YoY from $131.9M, driven by testing revenue up $18.7M
- Net margin 20.8% vs 14.5% YoY, with operating margin 10.9% vs 17.4%
- Testing revenue best performer: $146.4M, up 15%; biopharmaceutical revenue declined 106% from $8.7M
- Cash and investments $370.5M, down $42.4M; operating cash flow $121.3M
- Investing outflow $281.0M, including $153.2M acquisitions and $118.0M short-term investments
- Outlook: continued cash generation, with payer constraints, reimbursement pressure, tariffs and geopolitical risks as headwinds
Risk Factors
- No material changes from the 10-K risk factors
- Carried-forward risks include diagnostic adoption, reimbursement, competition, regulatory compliance, and operating losses
- Continued dependence on laboratory operations and uninterrupted testing capacity
- Ongoing exposure to healthcare customer concentration and payment delays
- Continued need for capital to fund operations and growth
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other VERACYTE, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.